TaiMed Biologics Inc. 4147

TPEX · Taiwan · Health Technology

TWD 61.40-0.60 (-0.97%)

Market closed· Oct 2, 2026, 5:30 AM UTC· TWD · Data may be delayed

Company news

Yahoo FinanceJul 07, 2026

TaiMed Biologics (4147) Receives TFDA Drug License Collection Notice for Trogarzo, Marking the Final Step Toward Commercial Launch in Taiwan

TAIPEI, July 07, 2026 (GLOBE NEWSWIRE) -- TaiMed Biologics (TPEX: 4147) announced today that its HIV therapy Trogarzo (ibalizumab; English name: Trogarzo Injection; Chinese name: 佐加洛注射劑) has officially received a Drug License Collection Notice from the Taiwan Food and Drug Administration (TFDA). Its commercialization partner, Orient EuroPharma Co., Ltd. ("Orient EuroPharma"; TPEX: 4120), will complete the required procedures to obtain the drug license in accordance with TFDA regulations, marking

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.

Prices may be delayed and are for informational purposes only - not investment advice.